Skip to main content
. 2022 Dec 1;4:100046. doi: 10.1016/j.obpill.2022.100046

Table 1.

Continuous data are summarized as mean and standard deviation (SD) or median and interquartile ranges (IQR). Categorical data are presented as frequencies and percentages. Significant p values are indicated in bold.

All patients preCOVID-19 COVID-19 p value
A. Baseline demographic information
N (%) 255 (100) 169 (66.2) 86 (33.7)
Age, years (SD) 48.2 (12.9) 49.1 (13.1) 46.6 (12.5) 0.13
Sex, Female (%) 193 (75.6) 126 (74.6) 67 (77.9) 0.55
Race, White (%) 245 (96.1) 167 (98.8) 78 (90.7) 0.0008

Baseline clinical information
Weight, kg (SD) 119.6 (29.3) 118 (23.8) 122.7 (37.9) 0.29
BMI, kg/m2(SD) 41.86 (8.5) 41.7 (7.4) 42.3 (10.2) 0.63
Overweight, n (%) 11 (4.3) 6 (3.6) 5 (5.8) 0.41
Obesity Class 1, n (%) 53 (20.8) 33 (19.5) 20 (23.3) 0.49
Obesity Class 2, n (%) 50 (19.6) 29 (17.2) 21 (24.4) 0.17
Obesity Class 3, n (%) 141 (55.3) 101 (59.8) 40 (46.5) 0.04
SBP, mmHg (SD) 129 (15) 129 (15) 129 (15) 0.90
DBP, mmHg (SD) 78 (22) 78 (10) 78 (12) 0.80
Glucose, mg/dL (SD) 122 (52) 129 (61) 109 (29) 0.03
HbA1c, % (SD) 7.0 (1.7) 7.1 (1.8) 6.5 (1.2) 0.11
Total Cholesterol, mg/dL (SD) 179 (49) 175 (40) 186 (61) 0.32
Total Triglycerides, mg/dL (SD) 151 (78) 160 (84) 133 (63) 0.06
LDL-cholesterol, mg/dl (SD) 103 (40) 96 (32) 115 (51) 0.04
HDL-cholesterol, mg/dl (SD) 50 (14) 48 (14) 53 (13) 0.08

B. Comorbidities
Dyslipidemia, n (%) 153 (60) 106 (62.7) 47 (54.7) 0.35
Diabetes mellitus, n (%) 80 (31.4) 58 (34.3) 22 (25.6) 0.15
Prediabetes, n (%) 23 (9.1) 13 (7.7) 10 (11.6) 0.36
Hypertension, n (%) 123 (48.2) 81 (47.9) 42 (48.8) 0.69
GERD, n (%) 66 (25.9) 44 (26) 22 (25.6) 0.93
Obstructive sleep apnea, n (%) 92 (36.1) 63 (37.3) 29 (33.7) 0.58
Degenerative joint disease, n (%) 83 (32.5) 67 (39.6) 16 (18.6) 0.0009
NAFLD, n (%) 19 (7.5) 13 (7.7) 6 (7.0) 0.89

C. Medication
Phentermine/topiramate, n (%) 124 (48.6) 92 (54.4) 32 (37.2) 0.01
Naltrexone/bupropion, n (%) 59 (23.1) 31 (18.3) 28 (32.6) 0.01
Liraglutide, n (%) 72 (28.2) 46 (27.2) 26 (30.2) 0.66

All p values < 0.05 were considered significant.

BMI, body mass index; DBP, diastolic blood pressure; GERD, gastroesophageal reflux disease; HbA1c, Hemoglobin A1c; HDL, High-density lipoprotein; LDL, low-density lipoprotein; NAFLD, nonalcoholic fatty liver disease; SBP, systolic blood pressure.

Diagnosis of obesity comorbidities was based on diagnoses listed by clinicians.